

# ISO 18562-1:2017-03 (E)

## Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 1: Evaluation and testing within a risk management process

---

<b>Contents</b>		<b>Page</b>
Foreword .....		iv
Introduction .....		v
1	Scope .....	1
2	Normative references .....	2
3	Terms and definitions .....	2
4	General principles applying to biocompatibility evaluation of medical devices .....	6
4.1	General .....	6
4.2	Type tests .....	7
4.3	Biocompatibility hazard identification .....	8
4.4	Extent of risk assessment .....	8
4.5	Biocompatibility evaluation plan .....	9
4.6	Selection of tests .....	10
4.7	Subsequent evaluation .....	10
5	Contamination of breathing gas from gas pathways .....	11
5.1	* Duration of use .....	11
5.2	Particulate matter (pm) emissions .....	13
5.3	Volatile organic compound (voc) emissions .....	13
5.4	Leachable substances in condensate .....	13
6	Adjustment for different patient groups .....	13
6.1	General considerations .....	13
6.2	Adjustment for body weight .....	13
6.3	* Deriving a permitted concentration from a tolerable exposure .....	14
7	* Deriving allowable limits .....	14
7.1	General process .....	14
7.2	For medical devices intended for limited exposure use (24 h) .....	15
7.3	For medical devices intended for prolonged exposure use (>24 h but <30 d) .....	16
7.4	For medical devices intended for permanent contact (30 d) .....	16
8	Risk benefit analysis .....	16
9	Assess the biocompatibility of the medical device .....	17
Annex A (informative)	Rationale and guidance .....	18
Annex B (informative)	Reference to the essential principles .....	20
Annex C (informative)	Terminology--Alphabetized index of defined terms .....	21
Bibliography .....		23